source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-15 06:30:00
| null |
NEW YORK, NY / ACCESSWIRE / JUNE 15, 2021 / ZEDGE, INC. (NYSE AMERICAN:ZDGE), A LEADING GLOBAL DEVELOPER OF MOBILE PHONE PERSONALIZATION AND ENTERTAINMENT APPS, TODAY ANNOUNCED THE AVAILABILITY OF BANKSY'S GRAFFITI WALLPAPERS IN THE ZEDGE PREMIUM MARKETPLACE. "WE ARE BEYOND EXCITED TO ESTABLISH A LICENSING RELATIONSHIP WITH FULL COLOUR BLACK TO OFFER HIGH DEFINITION IMAGES OF BANKSY'S GRAFFITI IN ZEDGE PREMIUM, OUR MARKETPLACE FOR ARTISTS," SAID JONATHAN REICH, CEO OF ZEDGE.
|
BANKSY'S GRAFFITI WALLPAPERS NOW AVAILABLE IN ZEDGE PREMIUM'S MARKETPLACE
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-08 06:30:00
| null |
NEW YORK, NY / ACCESSWIRE / JUNE 8, 2021 / ZEDGE, INC. (NYSE AMERICAN:ZDGE), A WORLDWIDE MOBILE PUBLISHING AND CONTENT PLATFORM PROVIDER, IS SET TO JOIN THE RUSSELL MICROCAP® INDEX. THE ADDITION IS SCHEDULED FOR THE CONCLUSION OF THE 2021 RUSSELL INDEXES ANNUAL RECONSTITUTION, EFFECTIVE AFTER THE US MARKETS OPEN ON JUNE 28, ACCORDING TO A PRELIMINARY LIST OF ADDITIONS POSTED JUNE 4.
|
ZEDGE TO JOIN RUSSELL MICROCAP(R) INDEX
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-20 06:30:00
| null |
ZEDGE TO PROVIDE FUNDING TO MEDFORD SPRING GRASSLAND CONSERVATION PROJECT TO OFFSET CARBON EMISSIONS, PRESERVE WILDLIFE AND SUPPORT BIODIVERSITY ANNOUNCES A LIMITED-TIME SPECIAL COLLECTION OF EARTH DAY CONTENT AVAILABLE IN ZEDGE'S HIGHLY POPULAR MOBILE PERSONALIZATION APP NEW YORK, NY / ACCESSWIRE / APRIL 20, 2021 / ZEDGE, INC. (NYSE AMERICAN:ZDGE), A LEADING GLOBAL DEVELOPER OF MOBILE PHONE PERSONALIZATION AND ENTERTAINMENT APPS, TODAY ANNOUNCED THAT IT IS NOW CARBON NEUTRAL THROUGH ITS FUNDING OF A CONSERVATION PROJECT THAT WILL OFFSET CARBON EMISSIONS FROM ITS OPERATIONS FOR ONE YEAR, WHILE ALSO SUPPORTING BIODIVERSITY. ZEDGE IS OFFSETTING THE EMISSIONS FROM ITS EMPLOYEES' TRAVEL AND OPERATIONS BY CONTRIBUTING THE ASSOCIATED CARBON VALUE TO SUPPORT THE MEDFORD SPRINGS GRASSLAND CONSERVATION PROJECT.
|
ZEDGE CELEBRATES EARTH DAY BY BECOMING CARBON NEUTRAL
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-23 17:23:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 23, 2020) - LEVI & KORSINSKY REMINDS SHAREHOLDERS THAT IT HAS COMMENCED AN INVESTIGATION OF ZEDGE, INC. (NYSE: ZDGE) CONCERNING POSSIBLE BREACHES OF FIDUCIARY DUTY. TO OBTAIN ADDITIONAL INFORMATION, GO TO:HTTPS://WWW.ZLK.COM/COMPENSATION2/ZEDGE-INC-INFORMATION-REQUEST-FORMOR CONTACT JOSEPH E. LEVI, ESQ. EITHER VIA EMAIL AT JLEVI@LEVIKORSINSKY.COM OR BY TELEPHONE AT (212) 363-7500. THERE IS NO COST OR OBLIGATION TO YOU.
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF AN INVESTIGATION CONCERNING POSSIBLE BREACHES OF FIDUCIARY DUTY BY CERTAIN OFFICERS AND DIRECTORS OF ZEDGE, INC.- ZDGE
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-06 09:30:00
| null |
ZEDGE INC - ON AUGUST 5, 2020, ELLIOT GIBBER RESIGNED AS INTERIM CEO OF COMPANY.ZEDGE INC - ON AUGUST 5, 2020, JONATHAN REICH RESIGNED AS CFO AND CHIEF OPERATING OFFICER OF CO.ZEDGE INC - ON AUGUST 5, 2020, BOARD APPOINTED JONATHAN REICH, TO SERVE AS CEO OF COMPANY.ZEDGE INC - ON AUGUST 5, 2020, BOARD APPOINTED YI TSAI, TO SERVE AS CFO AND TREASURER OF CO.
|
ZEDGE SAYS ELLIOT GIBBER RESIGNED AS INTERIM CEO
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-11 19:30:00
| null |
Q3 LOSS PER SHARE $0.03.Q3 REVENUE ROSE 8.7 PERCENT TO $2.1 MILLION.
|
ZEDGE REPORTS Q3 LOSS PER SHARE OF $0.03
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-11 19:30:00
| null |
Q2 EARNINGS PER SHARE $0.01.Q2 REVENUE ROSE 2.8 PERCENT TO $2.64 MILLION.
|
ZEDGE POSTS QUARTERLY EARNINGS PER SHARE OF $0.01
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-09 20:30:00
| null |
ZEDGE INC - FILES FOR OFFERING OF $5 MILLION OF CLASS B COMMON STOCK AND WARRANTS - SEC FILING.
|
ZEDGE INC FILES FOR OFFERING OF $5 MILLION OF CLASS B COMMON STOCK AND WARRANTS
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-12 12:30:00
| null |
ZEDGE INC - EFFECTIVE NOV 7, MICHAEL JONAS RESIGNED AS INTERIM CEO, BUT REMAINS AS A MEMBER OF BOARD OF DIRECTORS AND AS EXECUTIVE CHAIRMAN.ZEDGE INC - APPOINTED ELLIOT GIBBER TO SERVE AS INTERIM CEO EFFECTIVE NOV 7.
|
ZEDGE INC - EFFECTIVE NOV 7, MICHAEL JONAS RESIGNED AS INTERIM CEO, BUT REMAINS AS A MEMBER OF BOARD OF DIRECTORS AND AS EXECUTIVE CHAIRMAN
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-11 22:30:00
| null |
ON NOVEMBER 7, 2019, THE BOARD OF DIRECTORS OF ZEDGE, INC. ACCEPTED THE RESIGNATION OF ELLIOT GIBBER FROM THE BOARD OF DIRECTORS, IT’S AUDIT COMMITTEE, COMPENSATION COMMITTEE, CORPORATE GOVERNANCE COMMITTEE AND NOMINATING COMMITTEE. EFFECTIVE NOVEMBER 7, 2019, MICHAEL JONAS RESIGNED AS INTERIM CHIEF EXECUTIVE OFFICER OF THE COMPANY, BUT REMAINS AS A MEMBER OF THE BOARD OF DIRECTORS AND AS EXECUTIVE CHAIRMAN OF THE COMPANY. THE BOARD OF DIRECTORS OF THE COMPANY APPOINTED ELLIOT GIBBER, TO SERVE AS INTERIM CHIEF EXECUTIVE OFFICER EFFECTIVE NOVEMBER 7, 2019. ELLIOT GIBBER WAS A MEMBER OF THE BOARD OF DIRECTORS OF THE COMPANY FROM JANUARY 17, 2018 TO NOVEMBER 7, 2019.
|
ZEDGE, INC. ANNOUNCES MANAGEMENT CHANGES
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-24 19:30:00
| null |
Q4 LOSS PER SHARE $0.12.Q4 REVENUE $1.95 MILLION.
|
ZEDGE REPORTS Q4 LOSS PER SHARE OF $0.12
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-23 22:30:00
| null |
ZEDGE, INC. ANNOUNCED EARNINGS RESULTS FOR THE FULL YEAR ENDED JULY 31, 2019. FOR THE FULL YEAR, THE COMPANY ANNOUNCED SALES WAS USD 8.816 MILLION COMPARED TO USD 10.833 MILLION A YEAR AGO. OPERATING LOSS WAS USD 2.887 MILLION COMPARED TO USD 1.299 MILLION A YEAR AGO. NET LOSS WAS USD 3.344 MILLION COMPARED TO USD 1.563 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 0.33 COMPARED TO USD 0.16 A YEAR AGO.
|
ZEDGE, INC. REPORTS EARNINGS RESULTS FOR THE FULL YEAR ENDED JULY 31, 2019
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-10 22:30:00
| null |
ZEDGE, INC., Q4 2019 EARNINGS CALL, OCT 24, 2019
|
ZEDGE, INC., Q4 2019 EARNINGS CALL, OCT 24, 2019
|
ZDGE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-06 08:05:00
| null |
SCOTTSDALE, AZ / ACCESSWIRE / JUNE 6, 2023 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, IS PLEASED TO ANNOUNCE THAT CEO BRYAN MCLAREN WILL BE PARTICIPATING IN A LIVE MANAGEMENT MORNING BRIEFING EVENT AT GEOINVESTING.COM, A SUBSCRIPTION BASED ONLINE RESEARCH PLATFORM FOCUSED ON DELIVERING RESEARCH TO ITS MEMBERS ON MICROCAP COMPANIES THAT MEET OR ARE DOING THINGS TO POTENTIALLY MEET A CERTAIN SET OF QUALITATIVE AND QUANTITATIVE QUALITY FACTORS. PLEASE BE AWARE THAT ZONED PROPERTIES PARTICIPATION IN THE EVENT IS STRICTLY BY INVITATION ONLY, AND IS NOT PAYING ANY FEES TO ATTEND THE EVENT AND IS NOT BEING SPONSORED BY ANY THIRD PARTIES TO PARTICIPATE IN THE EVENT.
|
ZONED PROPERTIES, INC. (OTCQB:ZDPY) TO JOIN MANAGEMENT MORNING BRIEFING SKULL SESSION LIVE EVENT WITH GEOINVESTING WEDNESDAY JUNE 7TH AT 12:30 PM EST
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-15 08:05:00
| null |
PROPERTY INVESTMENT PORTFOLIO REVENUE GROWTH OF 56.5% IN FIRST QUARTER 2023 YEAR OVER YEAR SCOTTSDALE, AZ / ACCESSWIRE / MAY 15, 2023 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, TODAY ANNOUNCED ITS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS. THESE RESULTS PERTAIN TO THE THREE MONTHS ENDED MARCH 31, 2023.
|
ZONED PROPERTIES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-28 08:05:00
| null |
CASH FLOW PROVIDED BY OPERATIONS GROWTH OF 78% AND REVENUE GROWTH OF 46% IN 2022 YEAR OVER YEAR NATIONAL REAL ESTATE SERVICES INFRASTRUCTURE FUELS PIPELINE FOR NEW PROPERTY INVESTMENTS SCOTTSDALE, AZ / ACCESSWIRE / MARCH 28, 2023 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022. FINANCIAL HIGHLIGHTS: REVENUES WERE $2.66 MILLION FOR THE YEAR ENDED DECEMBER 31, 2022, COMPARED TO REVENUES OF $1.82 MILLION FOR THE YEAR ENDED DECEMBER 31, 2021, REPRESENTING AN INCREASE OF 46%.
|
ZONED PROPERTIES REPORTS FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-02 08:05:00
| null |
ACQUISITION DIVERSIFIES INVESTMENT PORTFOLIO AND PRODUCES 13.5% CAP RATE OVER THE LIFE OF THE LEASE TERM SCOTTSDALE, AZ / ACCESSWIRE / MARCH 2, 2023 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, TODAY ANNOUNCED THAT THE COMPANY HAS ACQUIRED AN INVESTMENT PROPERTY IN PLEASANT RIDGE, MICHIGAN (THE "INVESTMENT PROPERTY") AND ENTERED INTO A LONG-TERM, ABSOLUTE-NET LEASE AGREEMENT WITH NOXX CANNABIS TO OPERATE A RETAIL DISPENSARY. "WE ARE THRILLED TO ANNOUNCE THIS SIGNIFICANT TRANSACTION, WHICH MARKS OUR ENTRY INTO MICHIGAN AS AN INVESTOR IN REAL ESTATE.
|
ZONED PROPERTIES ACQUIRES CANNABIS RETAIL INVESTMENT PROPERTY IN MICHIGAN FOR $4.3 MILLION WITH ABSOLUTE-NET LEASE IN PLACE WITH NOXX CANNABIS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-02 09:05:00
| null |
THE COMPANY HAS APPROVED A LEASE AMENDMENT AND ASSIGNMENT AT ITS TEMPE PROPERTY THE COMPANY HAS SECURED A TENANT CAPITAL COMMITMENT OF $3 MILLION TO BE INVESTED IN PROPERTY IMPROVEMENTS SCOTTSDALE, AZ / ACCESSWIRE / DECEMBER 2, 2022 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, TODAY ANNOUNCED THAT THE COMPANY HAS APPROVED A LEASE AMENDMENT AND ASSIGNMENT AT ITS TEMPE PROPERTY GRANTING OPERATIONAL CONTROL TO GREEN DOT LABS AS THE PROPERTY'S NEW TENANT. "WE ARE EXTREMELY EXCITED TO WELCOME GREEN DOT LABS INTO THE ARIZONA MARKETPLACE AS THE NEW PRIMARY TENANT AT OUR PROPERTY IN TEMPE, ARIZONA," COMMENTED BRYAN MCLAREN, CHIEF EXECUTIVE OFFICER OF ZONED PROPERTIES.
|
ZONED PROPERTIES ADDS GREEN DOT LABS TO ITS TENANT ROSTER AS LEADING CANNABIS BRAND EXPANDS INTO ARIZONA
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-10 09:05:00
| null |
100% REVENUE GROWTH IN REAL ESTATE SERVICES YEAR-OVER-YEAR FOR NINE-MONTHS ENDED SEPTEMBER 30, 2022 60% TOTAL REVENUE GROWTH YEAR-OVER-YEAR FOR NINE-MONTHS ENDED SEPTEMBER 30, 2022 SECURED $4.5 MILLION DEBT FACILITY PROVIDES INITIAL BUYING POWER FOR NEW PROPERTY ACQUISITIONS SCOTTSDALE, AZ / ACCESSWIRE / NOVEMBER 10, 2022 / ZONED PROPERTIES®, INC. ("ZONED PROPERTIES" OR THE "COMPANY") (OTCQB:ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES, INCLUDING LEGALIZED CANNABIS, TODAY ANNOUNCED THE COMPANY'S FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022. "THE ZONED PROPERTIES PIPELINE AND CAPITAL ENGINE HAS BEEN TURNED ON.
|
ZONED PROPERTIES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-17 09:00:00
| null |
IN A HIGHLY REGULATED INDUSTRY FULL OF RED TAPE, LEV IS LEADING THE COMMERCIAL CANNABIS BOOM, HELPING CLIENTS TO CLOSE QUICKLY WITH FUNDING FROM FEDERAL INSTITUTIONS NEW YORK , AUG. 17, 2022 /PRNEWSWIRE/ -- LEV , THE COMMERCIAL REAL ESTATE (CRE) FINANCING PLATFORM, TODAY ANNOUNCED THE COMPLETION OF OVER $40 MILLION IN CANNABIS CRE LOANS ACROSS FIVE DIFFERENT SPONSORS, WITH AN ADDITIONAL $50 MILLION IN THE PIPELINE. BUILDING ON ITS MISSION OF OFFERING FAST, SECURE AND TRANSPARENT FINANCING, LEV WORKS WITH SERIOUS INVESTORS TO NAVIGATE COMPLEX HURDLES AT THE FEDERAL AND STATE LEVELS TO CLOSE CANNABIS DEALS 2X FASTER THAN TRADITIONAL METHODS.
|
LEV SECURES $41.5 MILLION IN CANNABIS CRE FINANCING ACROSS THE U.S., BREAKING DOWN BARRIERS TO FEDERAL LOANS IN THE MARKET
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-11 12:06:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. 60% REVENUE GROWTH YEAR-OVER-YEAR FOR SIX-MONTHS ENDED JUNE 30, 2022.
|
CORRECTING AND REPLACING ZONED PROPERTIES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-11 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. 60% REVENUE GROWTH YEAR-OVER-YEAR FOR SIX-MONTHS ENDED JUNE 30, 2022.
|
ZONED PROPERTIES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-12 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES SECURES INITIAL $4.5 MILLION DEBT FACILITY FOR CANNABIS REAL ESTATE. SECURED AGAINST TEMPE PROPERTY AS A 50% LOAN-TO-VALUE.
|
ZONED PROPERTIES SECURES INITIAL $4.5 MILLION DEBT FACILITY FOR CANNABIS REAL ESTATE
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 16:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES INVESTS IN ANAMITECH & GREENSPACE PROPTECH PLATFORM. EXPLORING STRATEGIC PARTNERSHIP WITH ANAMITECH TO SERVICE CANNABIS REAL ESTATE.
|
ZONED PROPERTIES INVESTS IN ANAMITECH & GREENSPACE PROPTECH PLATFORM
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-15 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES AND RIPCO PRESENT 1,000,000 SQUARE FOOT CANNABIS SITE LISTING IN UTICA, NEW YORK; FULLY APPROVED ZONING AND LOCAL SUPPORT.
|
ZONED PROPERTIES AND RIPCO PRESENT 1,000,000 SQUARE FOOT CANNABIS SITE LISTING
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-31 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES APPOINTS DAN GAUTHIER AS CHIEF LEGAL OFFICER. POSITION TO FOCUS ON LEGAL, COMPLIANCE, AND BUSINESS SYSTEMS FOR NATIONAL EXPANSION.
|
ZONED PROPERTIES APPOINTS DAN GAUTHIER AS CHIEF LEGAL OFFICER
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. 171% REVENUE GROWTH IN FIRST QUARTER YEAR-OVER-YEAR.
|
ZONED PROPERTIES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-12 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #ZDPY--ZONED PROPERTIES CLOSES OVER $50 MILLION IN COMMERCIAL REAL ESTATE TRANSACTIONS FOR CLIENTS & PROPERTY INVESTORS IN HIGHLY REGULATED INDUSTRIES.
|
ZONED PROPERTIES CLOSES OVER $50 MILLION IN COMMERCIAL REAL ESTATE TRANSACTIONS FOR CLIENTS & PROPERTY INVESTORS IN HIGHLY REGULATED INDUSTRIES
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-24 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #BROKERAGE--ZONED PROPERTIES REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS. 50% REVENUE GROWTH AND 188% INCREASE IN CASH PROVIDED BY OPERATIONS.
|
ZONED PROPERTIES REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-27 08:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #BROKERAGE--ZONED PROPERTIES ANNOUNCES THE APPOINTMENT OF JODY KANE TO THE BOARD OF DIRECTORS
|
ZONED PROPERTIES ANNOUNCES THE APPOINTMENT OF JODY KANE TO THE BOARD OF DIRECTORS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-10 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #BROKERAGE--ZONED PROPERTIES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS.
|
ZONED PROPERTIES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-24 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #BROKERAGE--ZONED PROPERTIES ANNOUNCES COMPLETION OF $8 MILLION EXPANSION AT ITS CHINO VALLEY CULTIVATION FACILITY.
|
ZONED PROPERTIES ANNOUNCES COMPLETION OF $8 MILLION EXPANSION AT ITS CHINO VALLEY CULTIVATION FACILITY
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-22 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #BROKERAGE--ZONED PROPERTIES®, INC. (THE “COMPANY”) (OTCQB: ZDPY), A LEADING REAL ESTATE DEVELOPMENT FIRM FOR EMERGING AND HIGHLY REGULATED INDUSTRIES INCLUDING REGULATED CANNABIS, TODAY ANNOUNCED THE EXPANSION OF ITS LEADERSHIP TEAM TO OVERSEE THE FIRM'S IN-HOUSE TRANSACTIONAL BROKERAGE DIVISION, ZONED PROPERTIES BROKERAGE. ZONED PROPERTIES HAS APPOINTED PATRICK MORONEY AS DIRECTOR OF REAL ESTATE TO FURTHER ADVANCE COMPANY SERVICES FOR EMERGING MARKETS. MORONEY HAS EXTE
|
ZONED PROPERTIES ESTABLISHES IN-HOUSE BROKERAGE TEAM EXPANDING COMMERCIAL REAL ESTATE OFFERINGS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-01 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #CANNABIS--ZONED PROPERTIES APPOINTS BEREKK BLACKWELL AS CHIEF OPERATING OFFICER, EXPANDING ITS EXECUTIVE TEAM AND COMMERCIAL REAL ESTATE SERVICES.
|
ZONED PROPERTIES APPOINTS BEREKK BLACKWELL AS CHIEF OPERATING OFFICER, EXPANDING ITS EXECUTIVE TEAM AND COMMERCIAL REAL ESTATE SERVICES
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-08 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #CANNABIS--ZONED PROPERTIES®, INC. (THE “COMPANY”) (OTCQB: ZDPY), A STRATEGIC REAL ESTATE DEVELOPMENT FIRM WHOSE PRIMARY MISSION IS TO PROVIDE REAL ESTATE AND SUSTAINABILITY SERVICES FOR THE REGULATED CANNABIS INDUSTRY, TODAY ANNOUNCED A COMPREHENSIVE UPDATE TO THE COMPANY'S GROWTH MODEL FEATURING EXPANDED REAL ESTATE SERVICES FOR THE REGULATED CANNABIS INDUSTRY AND ADVANCEMENTS IN ITS PROPERTY TECHNOLOGY (PROPTECH) DATA STRATEGY. ZONED PROPERTIES IS ENHANCING HOW HIGHL
|
ZONED PROPERTIES ENHANCES FUTURE GROWTH POTENTIAL WITH EXPANDED REAL ESTATE SERVICES AND PROPTECH PROJECT ADVANCEMENTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-07 09:05:00
| null |
SCOTTSDALE, ARIZ.--(BUSINESS WIRE)---- $ZDPY #CANNABIS--ZONED PROPERTIES EXPANDS REAL ESTATE SERVICES WITH PROPTECH DATA PROJECTS
|
ZONED PROPERTIES EXPANDS REAL ESTATE SERVICES WITH PROPTECH DATA PROJECTS
|
ZDPY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-03 06:01:00
| null |
COMPANY ANNOUNCEMENT – NO. 27 / 2023 ZEALAND PHARMA ANNOUNCES POSITIVE RESULTS FROM PART 1 OF MULTIPLE ASCENDING DOSE TRIAL WITH AMYLIN ANALOG ZP8396 DOSES OF 0.6 AND 1.2 MG ZP8396 ADMINISTERED ONCE-WEEKLY FOR SIX WEEKS LED TO 5.3% AND 5.1% MEAN WEIGHT LOSS AS COMPARED TO 2.6%, 3.6% AND 4.2% WEIGHT LOSS FOLLOWING SINGLE DOSES OF 0.7, 1.4 AND 2.4 MG ZP8396, ALREADY REPORTED PART 2 INVESTIGATES ONCE-WEEKLY DOSING FOR 16 WEEKS AND HAS BEEN INITIATED, EXPLORING SIGNIFICANTLY HIGHER DOSES OF ZP8396 BASED ON THE MILD ADVERSE EVENT PROFILE OBSERVED IN PART 1 OF THE TRIAL RESULTS SUPPORT CONTINUED DEVELOPMENT OF ZP8396 AS AN ALTERNATIVE TO GLP-1-BASED THERAPIES FOR THE MANAGEMENT OF OVERWEIGHT AND OBESITY COPENHAGEN, DENMARK, JULY 3, 2023 – ZEALAND PHARMA A/S (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA ANNOUNCES POSITIVE RESULTS FROM PART 1 OF MULTIPLE ASCENDING DOSE TRIAL WITH AMYLIN ANALOG ZP8396
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 13:32:00
| null |
PRESS RELEASE – NO. 8 / 2023 ZEALAND PHARMA SUBMITS NEW DRUG APPLICATION TO US FDA FOR DASIGLUCAGON IN CONGENITAL HYPERINSULINISM COPENHAGEN, DENMARK, JUNE 30, 2023 – ZEALAND PHARMA A/S (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA SUBMITS NEW DRUG APPLICATION TO US FDA FOR DASIGLUCAGON IN CONGENITAL HYPERINSULINISM
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-26 02:30:00
| null |
PRESS RELEASE – NO. 7 / 2023 ZEALAND PHARMA SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES TO THE EUROPEAN MEDICINES AGENCY COPENHAGEN, DENMARK JUNE 26, 2023 – ZEALAND PHARMA A/S (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES TO THE EUROPEAN MEDICINES AGENCY
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-24 11:35:00
| null |
PRESS RELEASE – NO. 6 / 2023 ZEALAND PHARMA PRESENTS RESULTS FROM PHASE 1 CLINICAL TRIAL OF AMYLIN ANALOG ZP8396 AT ADA SCIENTIFIC SESSIONS BODY WEIGHT REDUCTIONS REACHED UP TO A MEAN OF 4.2% FROM BASELINE (4.8% PLACEBO-CORRECTED) WITHIN ONE WEEK FOLLOWING A SINGLE DOSE OF ZP8396 AND WERE WELL-SUSTAINED OVER SIX WEEKS OF OBSERVATION IN DEVELOPMENT AS AN ALTERNATIVE NON-INCRETIN PEPTIDE THERAPY FOR THE POTENTIAL MANAGEMENT OF OVERWEIGHT AND OBESITY A 16-WEEK MULTIPLE ASCENDING DOSE (MAD) STUDY OF ZP8396 HAS BEEN INITIATED COPENHAGEN, DENMARK, JUNE 24, 2023 – ZEALAND PHARMA A/S (NASDAQ: ZEAL) (“ZEALAND”) (CVR-NO.
|
ZEALAND PHARMA PRESENTS RESULTS FROM PHASE 1 CLINICAL TRIAL OF AMYLIN ANALOG ZP8396 AT ADA SCIENTIFIC SESSIONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-23 17:27:00
| null |
INGELHEIM, GERMANY & COPENHAGEN, DENMARK--(BUSINESS WIRE)--NEARLY 19% WEIGHT LOSS IN PEOPLE WITH OVERWEIGHT OR OBESITY IN BOEHRINGER INGELHEIM AND ZEALAND PHARMA PHASE II TRIAL WITH SURVODUTIDE (BI 456906).
|
DATA SHOWS NEARLY 19% WEIGHT LOSS IN PEOPLE WITH OVERWEIGHT OR OBESITY IN BOEHRINGER INGELHEIM AND ZEALAND PHARMA PHASE II TRIAL WITH SURVODUTIDE (BI 456906)1
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-23 17:15:00
| null |
PRESS RELEASE NO. 5 / 2023 DATA SHOWS NEARLY 19% WEIGHT LOSS IN PEOPLE WITH OVERWEIGHT OR OBESITY IN BOEHRINGER INGELHEIM AND ZEALAND PHARMA PHASE II TRIAL WITH SURVODUTIDE (BI 456906)1 UP TO 40% OF PEOPLE WHO REACHED THE HIGHEST TWO DOSES OF SURVODUTIDE (BI 456906) ACHIEVED A WEIGHT LOSS OF AT LEAST 20%1 SURVODUTIDE HAS A NOVEL MECHANISM OF ACTION (AGONISM OF THE DUAL GCG/GLP-1 RECEPTORS) THAT MAY HAVE DIRECT EFFECTS ON ENERGY EXPENDITURE IN THE LIVER IN ADDITION TO DECREASING APPETITE2 DETAILED DATA WERE PRESENTED AT THE 2023 AMERICAN DIABETES ASSOCIATION'S 83RD SCIENTIFIC SESSIONS INGELHEIM, GERMANY, AND COPENHAGEN, DENMARK, 23 JUNE, 2023 – BOEHRINGER INGELHEIM AND ZEALAND PHARMA A/S (NASDAQ: ZEAL) TODAY ANNOUNCED ADDITIONAL DATA DEMONSTRATING SUPERIOR EFFICACY WITH SURVODUTIDE (ALSO KNOWN AS BI 456906) VERSUS PLACEBO IN PEOPLE WITH OVERWEIGHT OR OBESITY WITHOUT TYPE 2 DIABETES AFTER 46 WEEKS OF TREATMENT.1 THE FINDINGS WERE PRESENTED AT THE 2023 AMERICAN DIABETES ASSOCIATION'S 83RD SCIENTIFIC SESSIONS IN SAN DIEGO, CA, U.S. THE PHASE II STUDY INCLUDED TWO ANALYSES: PLANNED (ASSIGNED DOSE AT RANDOMIZATION, WHICH WAS ALSO THE PRIMARY ENDPOINT) AND ACTUAL (DOSE AT THE END OF TREATMENT).1 PEOPLE WHO COMPLETED THE STUDY ON THE 4.8 MG DOSE (ACTUAL TREATMENT ANALYSIS) ACHIEVED NEARLY 19% WEIGHT LOSS.1 AS PREVIOUSLY ANNOUNCED, THE PLANNED TREATMENT ANALYSIS DEMONSTRATED NEARLY 15% WEIGHT LOSS FOR ALL THOSE RANDOMIZED TO THE 4.8 MG DOSE.1 BODYWEIGHT REDUCTIONS WITH SURVODUTIDE HAD NOT REACHED A PLATEAU AT WEEK 46, SUGGESTING ADDITIONAL WEIGHT LOSS COULD BE ACHIEVED WITH LONGER TREATMENT DURATION.1 “GIVEN THE PREVALENCE OF OBESITY AND ITS MANY DISEASE-RELATED COMPLICATIONS, THERE IS A DIRE NEED FOR TREATMENTS THAT CAN HELP TREAT THE DISEASE OF OBESITY EFFECTIVELY,” SAID CAREL LE ROUX, MD, PH.D.
|
DATA SHOWS NEARLY 19% WEIGHT LOSS IN PEOPLE WITH OVERWEIGHT OR OBESITY IN BOEHRINGER INGELHEIM AND ZEALAND PHARMA PHASE II TRIAL WITH SURVODUTIDE (BI 456906)
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-08 16:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 25 / 2023 ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS COPENHAGEN, DENMARK, JUNE 8 , 202 3 – ZEALAND PHARMA A/S (“ZEALAND”) (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-06 11:00:00
| null |
PRESS RELEASE – NO. 4 / 2023 ZEALAND PHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES COPENHAGEN, DENMARK, JUNE 6, 2023 – ZEALAND PHARMA A/S (NASDAQ COPENHAGEN: ZEAL) (CVR-NO.
|
ZEALAND PHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-23 16:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 22 / 2023 ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS COPENHAGEN, DENMARK, MAY 23, 2023 – ZEALAND PHARMA A/S (“ZEALAND”) (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-12 15:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 21 / 2023 TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS COPENHAGEN, DENMARK, MAY 12, 2023 – ZEALAND PHARMA A/S (“ZEALAND”) (NASDAQ: ZEAL) (CVR-NO.
|
TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-11 01:00:00
| null |
COMPANY ANNOUNCEMENT - NO. 20 / 2023 ZEALAND PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2023 POSITIVE TOPLINE DATA FROM OBESITY PORTFOLIO ON TRACK FOR TWO REGULATORY SUBMISSIONS TARGETING RARE DISEASES STRENGTHENED BALANCE SHEET WITH DKK 1.5 BILLION IN APRIL RESULTING IN A RUNWAY TO MID-2026 COPENHAGEN, DENMARK, MAY 11, 2023 – ZEALAND PHARMA A/S (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2023
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-10 03:32:00
| null |
INGELHEIM, GERMANY, & COPENHAGEN, DENMARK--(BUSINESS WIRE)--BOEHRINGER INGELHEIM AND ZEALAND PHARMA ANNOUNCE PHASE II TRIAL SHOWED 14.9% WEIGHT LOSS IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT.
|
BOEHRINGER INGELHEIM AND ZEALAND PHARMA ANNOUNCE PHASE II TRIAL SHOWED 14.9% WEIGHT LOSS IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-10 02:30:00
| null |
BOEHRINGER INGELHEIM AND ZEALAND PHARMA ANNOUNCE PHASE II TRIAL SHOWED 14.9% WEIGHT LOSS IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT PHASE II DOSE-FINDING TRIAL MET PRIMARY ENDPOINT AFTER 46 WEEKS OF TREATMENT, REPRESENTING AN IMPORTANT ADVANCEMENT OF BOEHRINGER INGELHEIM'S CARDIO-RENAL-METABOLIC FOCUS AREAS FULL DATA WILL BE PRESENTED AT THE 2023 AMERICAN DIABETES ASSOCIATION'S 83RD SCIENTIFIC SESSIONS NOVEL DUAL GLUCAGON/GLP-1 RECEPTOR AGONIST BI 456906 IS PART OF THE COLLABORATION BETWEEN BOEHRINGER INGELHEIM AND ZEALAND PHARMA INGELHEIM, GERMANY, AND COPENHAGEN, DENMARK, 10 MAY, 2023 – BOEHRINGER INGELHEIM AND ZEALAND PHARMA A/S (NASDAQ: ZEAL) TODAY ANNOUNCED THAT PATIENTS TREATED WITH BI 456906 ACHIEVED UP TO 14.9% WEIGHT LOSS AFTER 46 WEEKS, USING THE PLANNED MAINTENANCE DOSE. THE PHASE II CLINICAL TRIAL EVALUATING THE EFFECT OF DIFFERENT DOSES OF THE NOVEL GLUCAGON/GLP-1 RECEPTOR DUAL AGONIST BI 456906 IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES (NCT04667377) MET ITS PRIMARY ENDPOINT.
|
BOEHRINGER INGELHEIM AND ZEALAND PHARMA ANNOUNCE PHASE II TRIAL SHOWED 14.9% WEIGHT LOSS IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-25 13:30:00
| null |
COMPANY ANNOUNCEMENT – NO. 17 / 2023 TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS COPENHAGEN, DENMARK, APRIL 25, 2023 – ZEALAND PHARMA A/S (“ZEALAND”) (NASDAQ: ZEAL) (CVR-NO.
|
TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-19 15:45:00
| null |
COMPANY ANNOUNCEMENT – NO. 15 / 2023 ZEALAND PHARMA LAUNCHES LONG-TERM INCENTIVE PROGRAM FOR ZEALAND'S BOARD OF DIRECTORS, CORPORATE MANAGEMENT AND EMPLOYEES FOR 2023 COPENHAGEN, DENMARK, APRIL 19, 2023 – ZEALAND PHARMA A/S (“ZEALAND”) (NASDAQ: ZEAL) (CVR-NO.
|
ZEALAND PHARMA LAUNCHES LONG-TERM INCENTIVE PROGRAM FOR ZEALAND'S BOARD OF DIRECTORS, CORPORATE MANAGEMENT AND EMPLOYEES FOR 2023
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-12 11:00:00
| null |
PRESS RELEASE – NO. 2 / 2023 ZEALAND PHARMA TO PARTICIPATE IN 22ND ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE COPENHAGEN, DENMARK, APRIL 12, 2023 – ZEALAND PHARMA A/S (NASDAQ COPENHAGEN: ZEAL) (CVR-NO.
|
ZEALAND PHARMA TO PARTICIPATE IN 22ND ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-04 02:32:00
| null |
COMPANY ANNOUNCEMENT – NO. 14 / 2023
|
ZEALAND PHARMA COMPLETES REGISTRATION OF CAPITAL INCREASE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-30 16:45:00
| null |
COMPANY ANNOUNCEMENT – NO. 11 / 2023
|
ZEALAND PHARMA ANNOUNCES COMPLETION OF A DIRECTED ISSUE AND PRIVATE PLACEMENT OF 6,578,948 MILLION NEW ORDINARY SHARES RAISING GROSS PROCEEDS OF DKK 1.5 BILLION
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-30 11:01:00
| null |
COMPANY ANNOUNCEMENT – NO. 10 / 2023
|
ZEALAND PHARMA ANNOUNCES DIRECTED ISSUE AND PRIVATE PLACEMENT OF APPROXIMATELY 6.5 MILLION NEW SHARES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-29 14:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 9 / 2023
|
ZEALAND PHARMA'S ANNUAL GENERAL MEETING 2023
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-28 04:54:00
| null |
COMPANY ANNOUNCEMENT – NO. 7 / 2023
|
ZEALAND PHARMA ANNOUNCES POSITIVE PHASE 1 CLINICAL RESULTS WITH AMYLIN ANALOGUE ZP8396
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-13 03:02:00
| null |
COMPANY ANNOUNCEMENT – NO. 6 / 2023
|
ZEALAND PHARMA PROVIDES UPDATE ON SILICON VALLEY BANK CLOSURE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-12 14:37:00
| null |
COMPANY ANNOUNCEMENT – NO. 5 / 2023
|
ZEALAND PHARMA PROVIDES STATEMENT ON SILICON VALLEY BANK CLOSURE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-10 10:45:00
| null |
COMPANY ANNOUNCEMENT – NO. 4 / 2023
|
TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-02 04:30:00
| null |
COMPANY ANNOUNCEMENT – NO. 1 / 2023
|
CORRECTION: ZEALAND PHARMA ANNOUNCES FULL YEAR RESULTS FOR 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-02 01:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 1 / 2023
|
ZEALAND PHARMA ANNOUNCES FULL YEAR RESULTS FOR 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-02 12:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 56/ 2022
|
TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-02 12:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 55/ 2022
|
ZEALAND PHARMA GRANTS SIGN-ON WARRANTS AND PERFORMANCE STOCK UNITS UNDER THE EMPLOYEE WARRANT PROGRAM AND MANAGEMENT LONG-TERM INCENTIVE PROGRAM
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-17 15:55:00
| null |
COMPANY ANNOUNCEMENT – NO. 53 / 2022
|
ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-17 11:29:00
| null |
COMPANY ANNOUNCEMENT – NO. 52 / 2022
|
TRANSACTIONS IN ZEALAND PHARMA SHARES AND/OR RELATED SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND/OR THEIR CLOSELY ASSOCIATED PERSONS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-10 09:00:00
| null |
COMPANY ANNOUNCEMENT NO. 51 / 2022
|
ZEALAND PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-01 12:00:00
| null |
PRESS RELEASE – NO. 7 / 2022
|
ZEALAND PHARMA ANNOUNCES PRESENTATIONS AT THE OBESITY SOCIETY ANNUAL MEETING
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-11 11:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 47 / 2022
|
ZEALAND PHARMA MAJOR SHAREHOLDER ANNOUNCEMENT: POLAR CAPITAL
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-10 11:12:00
| null |
COMPANY ANNOUNCEMENT – NO. 46 / 2022
|
ZEALAND PHARMA MAJOR SHAREHOLDER ANNOUNCEMENT: VAN HERK INVESTMENTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-07 02:42:00
| null |
COMPANY ANNOUNCEMENT – NO. 45 / 2022
|
ZEALAND PHARMA COMPLETES REGISTRATION OF CAPITAL INCREASE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 16:07:00
| null |
COMPANY ANNOUNCEMENT – NO. 44 / 2022
|
ZEALAND PHARMA ANNOUNCES COMPLETION OF A DIRECTED ISSUE AND PRIVATE PLACEMENT OF 4,975,000 NEW ORDINARY SHARES RAISING GROSS PROCEEDS OF APPROX. DKK 786 MILLION
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 11:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 43 / 2022
|
ZEALAND PHARMA ANNOUNCES DIRECTED ISSUE AND PRIVATE PLACEMENT OF APPROXIMATELY 4.5M NEW SHARES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-30 06:15:00
| null |
COMPANY ANNOUNCEMENT – NO. 41 / 2022
|
ZEALAND PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF GLEPAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME (EASE 1)
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-21 08:15:00
| null |
PRESS RELEASE – NO. 6 / 2022
|
ZEALAND PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 DATA FOR BI 456906 AT THE 58TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-19 02:00:00
| null |
PRESS RELEASE – NO. 5 / 2022
|
ZEALAND PHARMA PRESENTS DATA FROM PHASE 3 TRIAL OF DASIGLUCAGON IN CONGENITAL HYPERINSULINISM AT THE 60TH ANNUAL ESPE MEETING
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-13 16:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 40 / 2022
|
ZEALAND PHARMA GRANTS WARRANTS TO EMPLOYEES IN DENMARK
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-08 16:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 39 / 2022
|
ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-07 02:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 38 / 2022
|
ZEALAND PHARMA ANNOUNCES GLOBAL LICENSE AND DEVELOPMENT AGREEMENT WITH NOVO NORDISK FOR ZEGALOGUE® (DASIGLUCAGON)
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-24 04:30:00
| null |
COMPANY ANNOUNCEMENT – NO. 36 / 2022
|
ZEALAND PHARMA APPOINTS HENRIETTE WENNICKE AS CHIEF FINANCIAL OFFICER
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-18 14:58:00
| null |
COMPANY ANNOUNCEMENT – NO. 35 / 2022
|
ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-11 09:00:00
| null |
COMPANY ANNOUNCEMENT NO. 34 / 2022
|
ZEALAND PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST HALF OF 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-08 16:30:00
| null |
NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSS”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRS”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814
|
UPDATED NOTICE TO HOLDERS OF ADSS REGARDING TERMINATION OF DEPOSIT AGREEMENT
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-21 03:00:00
| null |
PARIS--(BUSINESS WIRE)--IKTOS, A COMPANY SPECIALIZED IN ARTIFICIAL INTELLIGENCE FOR NEW DRUG DESIGN, TODAY ANNOUNCED A RESEARCH COLLABORATION WITH ZEALAND PHARMA A/S (NASDAQ: ZEAL) (CVR-NO. 20045078), A BIOTECHNOLOGY COMPANY CHANGING LIVES WITH INNOVATIVE PEPTIDE-BASED MEDICINES TO CO-DEVELOP GENERATIVE AND PREDICTIVE AI TECHNOLOGIES FOR PEPTIDE DRUG DESIGN. IKTOS' AI TECHNOLOGY, BASED ON A COMPREHENSIVE DATA-DRIVEN CHEMICAL STRUCTURE GENERATION TECHNOLOGY, BRINGS NEW INSIGHTS INTO THE DRUG DIS
|
IKTOS AND ZEALAND PHARMA TO DEVELOP ARTIFICIAL INTELLIGENCE TECHNOLOGY FOR PEPTIDE DRUG DESIGN
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-15 16:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 29 / 20 2 2
|
TRANSACTIONS IN ZEALAND PHARMA A/S SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-10 13:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 28 / 202 2
|
ZEALAND PHARMA MAJOR SHAREHOLDER ANNOUNCEMENT: CREDIT SUISSE GROUP AG, 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-06 18:30:00
| null |
C OMPANY A NNOUNCEMENT – NO. 27 / 202 2
|
ZEALAND PHARMA PRESENTS DATA FROM PHASE 1 TRIAL OF DAPIGLUTIDE AT THE 82ND ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS AND ANNOUNCES DAPIGLUTIDE TO MOVE INTO PHASE 2 TRIAL FOR OBESITY
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-03 09:18:00
| null |
COMPANY ANNOUNCEMENT – NO . 26 / 202 2
|
ZEALAND PHARMA COMPLETES REGISTRATION OF CAPITAL INCREASE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-02 02:00:00
| null |
PRESS RELEASE - NO. 2 /2022
|
ZEALAND PHARMA ANNOUNCES APPOINTMENT OF DAVID M. KENDALL, M.D.
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-01 11:30:00
| null |
COMPANY ANNOUNCEMENT – NO . 3 / 202 2
|
ZEALAND PHARMA ANNOUNCES DIRECTED ISSUE AND PRIVATE PLACEMENT CORRESPONDING TO APPROX. 6.6 % OF EXISTING SHARE CAPITAL
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-31 16:08:00
| null |
COMPANY ANNOUNCEMENT – NO. 2 / 20 2 2
|
TRANSACTIONS IN ZEALAND PHARMA A/S SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-31 07:00:00
| null |
P RESS RELEASE – NO. 1 / 202 2
|
ZEALAND PHARMA ANNOUNCES MULTIPLE PRESENTATIONS AT THE 82ND ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS, INCLUDING INITIAL CLINICAL DATA ON GLP-1/GLP-2 DUAL AGONIST DAPIGLUTIDE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-25 16:30:00
| null |
COMPANY ANNOUNCEMENT – NO. 23 / 20 2 2
|
ZEALAND PHARMA LAUNCHES LONG-TERM INCENTIVE PROGRAM FOR ZEALAND'S CORPORATE MANAGEMENT AND EMPLOYEES FOR 2022
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-25 16:27:00
| null |
COMPANY ANNOUNCEMENT – NO. 24 / 20 2 2
|
TRANSACTIONS IN ZEALAND PHARMA A/S SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-19 07:35:00
| null |
COMPANY ANNOUNCEMENT – NO. 22 / 20 2 2
|
ZEALAND PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF DASIGLUCAGON IN PEDIATRIC PATIENTS WITH CONGENITAL HYPERINSULINISM (CHI)
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-17 06:04:00
| null |
COMPANY ANNOUNCEMENT – NO. 21 / 202 2
|
ZEALAND PHARMA ANNOUNCES ASSET PURCHASE AGREEMENT WITH MANNKIND CORPORATION FOR V-GO® INSULIN DELIVERY DEVICE
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 12:05:00
| null |
COMPANY ANNOUNCEMENT – NO. 19 / 20 2 2
|
TRANSACTIONS IN ZEALAND PHARMA A/S SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 09:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 18 / 2022
|
ZEALAND PHARMA PROVIDES UPDATE ON REFOCUSED STRATEGY PRIORITIZING RESEARCH AND DEVELOPMENT
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-09 21:17:00
| null |
C OMPANY A NNOUNCEMENT – NO. 16 / 202 2
|
ZEALAND PHARMA AMENDS FINANCING AGREEMENT WITH OBERLAND CAPITAL AS PART OF COMPANY'S REFOCUSED STRATEGY
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-22 11:00:00
| null |
COMPANY ANNOUNCEMENT – NO. 15 / 20 2 2
|
TRANSACTIONS IN ZEALAND PHARMA A/S SECURITIES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
|
ZEAL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.